TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12072596

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b (3 MU three times weekly) for 52 weeks in combination with ribavirin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Interferon alpha‐2b (3 MU three times weekly) for 52 weeks without ribavirin (placebo)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b with ribavirin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Interferon alpha‐2b without ribavirin (placebo)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 116
Study: 11161866

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall and recurrence-free survival
Number of subjects: 70
Study: 9390701

Group type: EXPERIMENTAL
Intervention: Group I (normal ultrasound or uncomplicated hemorrhage)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Group II (complicated hemorrhage or parenchymal lesions)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Subjects with good outcome (McCarthy General Cognitive Index score > 80)
Number of subjects: 53
Study: 7955935

Group type: EXPERIMENTAL
Intervention: Exercise (ergometer bicycling at 65% of maximal aerobic capacity)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (resting for 2 hours)
Number of subjects: 20
Study: 3622594

Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg thrice daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg thrice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29848836

Group type: EXPERIMENTAL
Intervention: Immune-modulating nutrient-enriched enteral nutrition (EN)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard enteral nutrition (EN)
Number of subjects: 34
Study: 26796694

Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23295354

Group type: EXPERIMENTAL
Intervention: MIM+ mentor group
Number of subjects: 28

Group type: COMPARATOR
Intervention: MIM-only group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 23835818

Group type: EXPERIMENTAL
Intervention: MD‐Ed+A (physician education and patient activation)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: MD‐Ed (physician education alone)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Control (usual education)
Number of subjects: 712
Study: 20601163

Group type: EXPERIMENTAL
Intervention: Feedback intervention - patients complete monthly symptom surveys, and severity of symptoms is mailed to the renal provider with treatment options.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Management intervention - patients complete monthly symptom surveys and are evaluated by a symptom management nurse who provides recommendations for treatment.
Number of subjects: 250
Study: 18807108

Group type: EXPERIMENTAL
Intervention: 500 microg phylloquinone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 15861085

Group type: EXPERIMENTAL
Intervention: Tumescent lidocaine injection into the neck (lidocaine 0.1%, NaHCO3 12.5 mEq/L, epinephrine 1:1,000,000, 7 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tumescent lidocaine injection into the thighs (lidocaine 0.1%, NaHCO3 12.5 mEq/L, epinephrine 1:1,000,000, 7 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tumescent lidocaine injection into the neck
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tumescent lidocaine injection into the thighs
Number of subjects: 8
Study: 12830403

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 113

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 113
Study: 10378864

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a (Avonex) treatment for 104 weeks
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a (Avonex) treatment
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Baseline CSF parameters (IgG index, kappa light chains, OCB)
Number of subjects: 301
Study: 9017566

Group type: EXPERIMENTAL
Intervention: Matched caseworkers (Anglo group)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Not matched caseworkers (Anglo group)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Matched and nonmatched subgroups (all ethnic groups)
Number of subjects: 610
Study: 1658942

Group type: EXPERIMENTAL
Intervention: Logiparin 50 mg/kg body weight once daily for 7 days, starting 2 hours preoperatively.
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo once daily for 7 days, starting 2 hours preoperatively.
Number of subjects: 210
Study: 30118625

Group type: EXPERIMENTAL
Intervention: Palm presser
Number of subjects: 0

Group type: COMPARATOR
Intervention: TFT
Number of subjects: 0
Study: 30328725

Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost/timolol fixed combination (TTFC) administered in the evening (20:00) for 3 months
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost/timolol fixed combination (TTFC) administered in the morning (08:00) for 3 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Preserved latanoprost monotherapy
Number of subjects: 42
Study: 26383099

Group type: EXPERIMENTAL
Intervention: Insect therapy (5 crickets in a cage with sufficient fodder and a detailed instruction manual)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Insect therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (only health advice)
Number of subjects: 94
Study: 24899596

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (2710 mg EPA/day and 2040 mg DHA/day for one month)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 48
Study: 22329674

Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 20398020

Group type: EXPERIMENTAL
Intervention: Low-dose prednisone comedication
Number of subjects: 210

Group type: COMPARATOR
Intervention: Non-low-dose prednisone (control group)
Number of subjects: 210
Study: 17993770

Group type: EXPERIMENTAL
Intervention: 5 h i.v. infusion of active ghrelin
Number of subjects: 25
Study: 15790912

Group type: EXPERIMENTAL
Intervention: Prescribed patching for 3 hours
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Prescribed patching for 6 hours
Number of subjects: 52

Group type: COMPARATOR
Intervention: No patching (0 hours)
Number of subjects: 52
Study: 11796537

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9795454

Group type: EXPERIMENTAL
Intervention: Anti-regurgitation formula (casein/whey ratio 80/20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular adapted formula (casein/whey ratio 40/60)
Number of subjects: 40
Study: 8568081

Group type: EXPERIMENTAL
Intervention: High level of child negative affect (NA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No negative affect (NNA)
Number of subjects: 39
Study: 2551805

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 640917

Group type: EXPERIMENTAL
Intervention: Tests 1 through 12 (various intervals of 10, 20, 30, or 40 minutes between tests)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standard Reference (SR) test
Number of subjects: 5
Study: 30647190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Baricitinib 8 mg
Number of subjects: 301
Study: 28401842

Group type: EXPERIMENTAL
Intervention: Parent-child attachment-based video-feedback intervention (8-week duration)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study: 25778837

Group type: EXPERIMENTAL
Intervention: Parental trait anxiety pre- and post-treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Parental anxiety
Number of subjects: 31
Study: 24051110

Group type: EXPERIMENTAL
Intervention: SEMSA-C (Chinese version of the self-efficacy measures for sleep apnea questionnaire)
Number of subjects: 100
Study: 21885885

Group type: EXPERIMENTAL
Intervention: Supplemental PA intervention (8-week individualized counseling and community-based PA component)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard care (diabetes education program)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups (Standard care and Supplemental PA intervention)
Number of subjects: 96
Study: 19969163

Group type: EXPERIMENTAL
Intervention: rMV (100Hz, 300-500 microm, in three 10-minute sessions a day for 3 consecutive days) applied to voluntary contracted quadriceps
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rMV (100Hz, 300-500 microm, in three 10-minute sessions a day for 3 consecutive days) applied to relaxed quadriceps
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo stimulation (nonvibrated group)
Number of subjects: 60
Study: 17391323

Group type: EXPERIMENTAL
Intervention: CNS 5161 HCl 250 microg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CNS 5161 HCl 500 microg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14998738

Group type: EXPERIMENTAL
Intervention: Increased perceived personal influence
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Expectation of failure
Number of subjects: 47
Study: 11580151

Group type: EXPERIMENTAL
Intervention: Interferon continued for 1 more year with gradual reduction of the dose
Number of subjects: 57

Group type: COMPARATOR
Intervention: Interferon stopped
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Interferon continued
Number of subjects: 57
Study: 9578788

Group type: EXPERIMENTAL
Intervention: DTPw-HB vaccine booster dose at 18 months of age
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTPw-HB vaccine
Number of subjects: 0
Study: 8424283

Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) with halothane and opioids
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with regional anesthesia (RA) with epidural bupivacaine (0.25%) and adrenaline
Number of subjects: 20
Study: 3475196

Group type: EXPERIMENTAL
Intervention: Cefotiam in 2 doses of 2 g for 5 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cefotiam in 2 doses of 2 g only perioperatively
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ceftriaxone in a single dose of 2 g preoperatively
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low-dose prophylaxis with 1 g ceftriaxone preoperatively
Number of subjects: 65
Study: 30995643

Group type: EXPERIMENTAL
Intervention: Knowledge about HIV/AIDS transmission
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Understanding of HIV/AIDS
Number of subjects: 346
Study: 29022387

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum IS-10506 (1010 cfu/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (skim milk-Avicel)
Number of subjects: 22
Study: 25848848

Group type: EXPERIMENTAL
Intervention: 550 mg NSAID + paracervical block (group 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 550 mg NSAID + paracervical analgesic cream (group 3)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 550 mg NSAID (group 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 550 mg NSAID + intrauterine analgesic instillation (group 4)
Number of subjects: 75
Study: 23578600

Group type: EXPERIMENTAL
Intervention: CAS
Number of subjects: 254

Group type: COMPARATOR
Intervention: CEA
Number of subjects: 254
Study: 21282434

Group type: COMPARATOR
Intervention: Conventional dose of sulfadoxine-pyrimethamine (25/1.25 mg/kg of body weight)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Double dose of sulfadoxine-pyrimethamine (50/2.5 mg/kg of body weight)
Number of subjects: 70
Study: 19174830

Group type: EXPERIMENTAL
Intervention: Vitamin A plus zinc
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (including vitamin A and zinc)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Vitamin A alone
Number of subjects: 373
Study: 16924024

Group type: EXPERIMENTAL
Intervention: Patients with IGE
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 19
Study: 15368799

Group type: EXPERIMENTAL
Intervention: Family History Score (FHS) based on presence of coronary heart disease, hypertension, hypercholesterolaemia, and diabetes mellitus in first-degree relatives
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Family History Score (FHS)
Number of subjects: 1926
Study: 11401052

Group type: EXPERIMENTAL
Intervention: 200 parts per billion SO2
Number of subjects: 24

Group type: COMPARATOR
Intervention: Air
Number of subjects: 24
Study: 9655010

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 152

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 152
Study: 8069645

Group type: EXPERIMENTAL
Intervention: i.v. caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 0
Study: 2973693

Group type: EXPERIMENTAL
Intervention: Heat-treated recombinant DNA hepatitis B vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaccine stored at 4 degrees C
Number of subjects: 0
Study: 29675875

Group type: EXPERIMENTAL
Intervention: Supportive care bundle (modulation of the infants' states, non‐nutritive sucking, facilitated tucking, and oral sucrose feeding)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care (control condition including routine procedures, positioning, and gentle touch)
Number of subjects: 65
Study: 26827233

Group type: EXPERIMENTAL
Intervention: Long spine board (LSB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretcher mattress
Number of subjects: 0
Study: 25714528

Group type: EXPERIMENTAL
Intervention: Tranilast Group (n=15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control Group (n=14)
Number of subjects: 29
Study: 23275012

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Western medicine (WM)
Number of subjects: 320
Study: 20697092

Group type: EXPERIMENTAL
Intervention: Induction therapy with single-agent rituximab followed by 4 cycles of maintenance therapy every 2 months (prolonged exposure)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Observation (no further treatment after induction)
Number of subjects: 202
Study: 18215332

Group type: EXPERIMENTAL
Intervention: One-year school-based exercise intervention program (40 minutes of general physical activity per school day, totaling 200 minutes/week)
Number of subjects: 53

Group type: COMPARATOR
Intervention: General Swedish physical education curriculum (60 minutes/week)
Number of subjects: 53
Study: 17015058

Group type: EXPERIMENTAL
Intervention: d-methamphetamine (0.25 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d-methamphetamine (0.5 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: racemic methamphetamine (0.5 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: l-methamphetamine (0.5 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: l-methamphetamine (0.25 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: racemic methamphetamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 14551525

Group type: EXPERIMENTAL
Intervention: Early statin therapy started before discharge from hospital after an acute coronary syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early statin therapy
Number of subjects: 0
Study: 9613022

Group type: EXPERIMENTAL
Intervention: Positive feedback on diagnostic measure
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Negative feedback on diagnostic measure
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Ambiguous feedback on diagnostic measure
Number of subjects: 192
Study: 8178906

Group type: EXPERIMENTAL
Intervention: Monophasic ethinyl estradiol/norgestimate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triphasic ethinyl estradiol/norgestimate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both monophasic and triphasic ethinyl estradiol/norgestimate
Number of subjects: 0
Study: 2491867

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator (rt-PA) 100 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Intravenous streptokinase 1.5 million units
Number of subjects: 171
Study: 184771

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid therapy (dexamethasone)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Steroid-antibiotic preparation
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Corticosteroids (various formulations)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 31533704

Group type: EXPERIMENTAL
Intervention: Positive outcome
Number of subjects: 395

Group type: COMPARATOR
Intervention: Industry funding disclosure
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Negative outcome
Number of subjects: 395
Study: 27562036

Group type: EXPERIMENTAL
Intervention: Behavior-based sexual assault prevention intervention (empowerment, gender relations, self-defense for girls; healthy gender norms for boys)
Number of subjects: 5686

Group type: EXPERIMENTAL
Intervention: Behavior-based sexual assault prevention intervention
Number of subjects: 5686

Group type: COMPARATOR
Intervention: Health and hygiene curriculum (control group)
Number of subjects: 5686
Study: 23594381

Group type: EXPERIMENTAL
Intervention: Web-based intervention supplemented with SMS, including access to a tailor-made interactive website and periodic updates with school and leisure activities.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what the control entails).
Number of subjects: 0
Study: 21148045

Group type: COMPARATOR
Intervention: Oral bosutinib 100 mg alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral bosutinib 100 mg with ketoconazole 400 mg
Number of subjects: 0
Study: 19824222

Group type: EXPERIMENTAL
Intervention: Tesofensine 0.25 mg
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Tesofensine 0.5 mg
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Tesofensine 1.0 mg
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 17679042

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40 mg (second study)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg (second study)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg (second study)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Valsartan 160 mg (second study)
Number of subjects: 20
Study: 15060765

Group type: EXPERIMENTAL
Intervention: Antiseptic-coated catheter (ACC)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Standard non-coated catheter (NCC)
Number of subjects: 397
Study: 11457746

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 37

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 37
Study: 9884850

Group type: EXPERIMENTAL
Intervention: Incremental spinal anaesthesia (bupivacaine 0.5% plain)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Single-dose spinal anaesthesia (2.5 mL of bupivacaine 0.5% plain)
Number of subjects: 43

Group type: COMPARATOR
Intervention: General anaesthesia (fentanyl, thiopentone, atracurium, enflurane, N2O/O2)
Number of subjects: 43
Study: 7741492

Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: ceftriaxone/gentamicin
Number of subjects: 50
Study: 2210673

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 778366

Group type: EXPERIMENTAL
Intervention: Combined ampicillin and gentamicin therapy with intrathecal administration of gentamicin
Number of subjects: 117

Group type: COMPARATOR
Intervention: Combined ampicillin and gentamicin therapy without intrathecal administration of gentamicin
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 117
Study: 30636504

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (8 or 12 mg according to weight)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 27859267

Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 26000677

Group type: EXPERIMENTAL
Intervention: Kiva VCF Treatment System
Number of subjects: 304

Group type: COMPARATOR
Intervention: Balloon Kyphoplasty (BK)
Number of subjects: 304
Study: 23758106

Group type: EXPERIMENTAL
Intervention: Essential oils
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amine/stannous fluoride
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chlorhexidine digluconate (0.12%)
Number of subjects: 24
Study: 21570523

Group type: EXPERIMENTAL
Intervention: Disease Management (DM) program that reduced readmissions by 21%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluated published DM programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bundled payments including care over 180 days
Number of subjects: 0
Study: 19013521

Group type: EXPERIMENTAL
Intervention: 0.1% timolol hydrogel
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% aqueous timolol
Number of subjects: 0
Study: 16684198

Group type: EXPERIMENTAL
Intervention: Guided participation (GP) with printed guidelines for managing VLBW infant health problems.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care with printed guidelines (GL) for managing VLBW infant health problems.
Number of subjects: 31
Study: 16359800

Group type: EXPERIMENTAL
Intervention: Faces Pain Scale-Revised (FPS-R)
Number of subjects: 112